NYSE · CIK 0001005101
MGLD Marygold Companies, Inc.
Insider trading from SEC Form 4. Last filing Dec 12, 2025. Close $2.02 on Oct 9, 2026, +133% from the 52-week low and -0% from the high.
Marygold Companies, Inc. (MGLD) has 18 SEC Form 4 filings on file from 7 insiders, the latest filed on Dec 12, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
7 open-market trades have been scored at MGLD. The newest: Nicholas & Melinda Gerber Living Trust (Chief Executive Officer) bought $23k of stock on Dec 10, 2025, filed Dec 12, 2025, scored 33 (weak). The largest of the 7 shown: Nicholas & Melinda Gerber Living Trust (Chief Executive Officer) bought $75k on Nov 21, 2024, scored 28 (weak).
MGLD closed at $2.02 on Oct 9, 2026, 133% above its 52-week low and 0% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Marygold Companies, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Nicholas & Melinda Gerber Living Trust Chief Executive Officer buy | $23k 25,000 shares | +0% | +34% from low-56% from high | |
| 33Weak | Nicholas & Melinda Gerber Living Trust Chief Executive Officer buy | $16k 15,352 shares | +0% | +54% from low-49% from high | |
| 28Weak | Nicholas & Melinda Gerber Living Trust Chief Executive Officer buy | $21k 20,000 shares | +0% | +47% from low-51% from high | |
| 35Weak | Nicholas & Melinda Gerber Living Trust Chief Executive Officer buy | $50k 50,000 shares | +0% | +35% from low-50% from high | |
| 33Weak | Nicholas & Melinda Gerber Living Trust Chief Executive Officer buy | $73k 42,149 shares | +0% | - | |
| 35Weak | Carolyn M. Yu Chief Legal & Continuity Off sell | $11k 7,000 shares | -100% | - | |
| 28Weak | Nicholas & Melinda Gerber Living Trust Chief Executive Officer buy | $75k 50,000 shares | +0% | - |
Transactions
Every row filed, 33 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | Nicholas & Melinda Gerber Living Trust Chief Executive Officer | POpen-market purchase Common Stock | +25,000 | $0.93 | $23k | 18,751,125 | Dec 12, 2025 |
| Dec 3, 2025 | Nicholas & Melinda Gerber Living Trust Chief Executive Officer | POpen-market purchase Common Stock | +15,352 | $1.03 | $16k | 18,726,125 | Dec 4, 2025 |
| Nov 20, 2025 | Nicholas & Melinda Gerber Living Trust Chief Executive Officer | POpen-market purchase Common Stock | +20,000 | $1.05 | $21k | 18,710,773 | Nov 21, 2025 |
| Nov 7, 2025 | James S Alexander director | AGrant or award Common Stock | +4,854 | $1.03 | $5,000 | 14,676 | Nov 10, 2025 |
| Nov 7, 2025 | Matt Gonzalez director | AGrant or award Common Stock | +4,854 | $1.03 | $5,000 | 14,779 | Nov 10, 2025 |
| Nov 7, 2025 | Erin Grogan director | AGrant or award Common Stock | +4,854 | $1.03 | $5,000 | 14,779 | Nov 10, 2025 |
| Nov 7, 2025 | Joya Harris director | AGrant or award Common Stock | +4,854 | $1.03 | $5,000 | 14,779 | Nov 10, 2025 |
| Nov 7, 2025 | Derek Jason Mullins director | AGrant or award Common Stock | +4,854 | $1.03 | $5,000 | 14,779 | Nov 10, 2025 |
| Sep 8, 2010 | Matt Gonzalez director | MOption exercise Series B, Convertible, Voting, Preferred Stockderivative | +11,670 | $0.24 | $2,801 | 11,670 | Nov 10, 2025 |
| Jun 20, 2025 | Nicholas & Melinda Gerber Living Trust Chief Executive Officer | POpen-market purchase Common Stock | +50,000 | $1.00 | $50k | 18,690,773 | Jun 24, 2025 |
| Dec 20, 2024 | Nicholas & Melinda Gerber Living Trust Chief Executive Officer | POpen-market purchase Common Stock | +42,149 | $1.72 | $73k | 18,510,915 | Dec 23, 2024 |
| Mar 29, 2023 | Matt Gonzalez director | AGrant or award Common Stock | +2,924 | $1.71 | $5,000 | 2,924 | Dec 12, 2024 |
| Mar 29, 2023 | Derek Jason Mullins director | AGrant or award Common Stock | +2,924 | $1.71 | $5,000 | 2,924 | Dec 12, 2024 |
| Mar 29, 2023 | Joya Harris director | AGrant or award Common Stock | +2,924 | $1.71 | $5,000 | 2,924 | Dec 12, 2024 |
| Mar 29, 2023 | Erin Grogan director | AGrant or award Common Stock | +2,924 | $1.71 | $5,000 | 2,924 | Dec 12, 2024 |
| Mar 29, 2023 | Matt Gonzalez director | AGrant or award Common Stock | +2,924 | $1.71 | $5,000 | 2,924 | Dec 12, 2024 |
| Jul 6, 2023 | James S Alexander director | AGrant or award Common Stock | +2,821 | $1.02 | $2,877 | 2,821 | Dec 12, 2024 |
| Dec 6, 2024 | Matt Gonzalez director | AGrant or award Common Stock | +3,623 | $1.38 | $5,000 | 6,444 | Dec 12, 2024 |
| Dec 6, 2024 | Derek Jason Mullins director | AGrant or award Common Stock | +3,623 | $1.38 | $5,000 | 6,444 | Dec 12, 2024 |
| Dec 6, 2024 | Joya Harris director | AGrant or award Common Stock | +3,623 | $1.38 | $5,000 | 6,444 | Dec 12, 2024 |
| Dec 6, 2024 | Erin Grogan director | AGrant or award Common Stock | +3,623 | $1.38 | $5,000 | 6,444 | Dec 12, 2024 |
| Dec 6, 2024 | Matt Gonzalez director | AGrant or award Common Stock | +3,623 | $1.38 | $5,000 | 6,444 | Dec 12, 2024 |
| Dec 6, 2024 | James S Alexander director | AGrant or award Common Stock | +3,623 | $1.38 | $5,000 | 6,444 | Dec 12, 2024 |
| Dec 9, 2024 | Matt Gonzalez director | AGrant or award Common Stock | +3,378 | $1.48 | $4,999 | 9,925 | Dec 12, 2024 |
| Dec 9, 2024 | Derek Jason Mullins director | AGrant or award Common Stock | +3,378 | $1.48 | $4,999 | 9,925 | Dec 12, 2024 |
| Dec 9, 2024 | Joya Harris director | AGrant or award Common Stock | +3,378 | $1.48 | $4,999 | 9,925 | Dec 12, 2024 |
| Dec 9, 2024 | Erin Grogan director | AGrant or award Common Stock | +3,378 | $1.48 | $4,999 | 9,925 | Dec 12, 2024 |
| Dec 9, 2024 | Matt Gonzalez director | AGrant or award Common Stock | +3,378 | $1.48 | $4,999 | 9,925 | Dec 12, 2024 |
| Dec 9, 2024 | James S Alexander director | AGrant or award Common Stock | +3,378 | $1.48 | $4,999 | 9,822 | Dec 12, 2024 |
| Sep 8, 2010 | Matt Gonzalez director | MOption exercise Series B, Convertible, Voting, Preferred Stockderivative | +11,670 | $0.24 | $2,801 | 11,670 | Dec 12, 2024 |
| Sep 8, 2010 | Matt Gonzalez director | MOption exercise Series B, Convertible, Voting, Preferred Stockderivative | +11,670 | $0.24 | $2,801 | 11,670 | Dec 12, 2024 |
| Nov 21, 2024 | Carolyn M. Yu Chief Legal & Continuity Off | SOpen-market sale Common Stockindirect: By Spouse | -7,000 | $1.51 | $11k | 0 | Nov 25, 2024 |
| Nov 21, 2024 | Nicholas & Melinda Gerber Living Trust Chief Executive Officer | POpen-market purchase Common Stock | +50,000 | $1.51 | $75k | 18,468,766 | Nov 25, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- James S Alexanderdirector
- Matt Gonzalezdirector
- Erin Grogandirector
- Joya Harrisdirector
- Derek Jason Mullinsdirector
- Nicholas & Melinda Gerber Living TrustChief Executive Officer
- Carolyn M. YuChief Legal & Continuity Off
Questions about MGLD
Answered from the filings on this page, as of the latest one.
Are insiders buying MGLD?
No. In the last 90 days no insider at Marygold Companies, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade MGLD on the open market?
Nicholas & Melinda Gerber Living Trust (Chief Executive Officer) bought $23k of MGLD on Dec 10, 2025 and filed the Form 4 on Dec 12, 2025. InsiderTell scored 33 (weak).
How many insiders file Form 4 at Marygold Companies, Inc.?
7 people have filed a Form 4 at Marygold Companies, Inc., among them James S Alexander (director), Matt Gonzalez (director), Erin Grogan (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.